MindWalk Holdings Corp.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- MindWalk Holdings Corp. (NYSE American: HYFT) develops and provides artificial intelligence (AI) solutions focused on enterprise productivity, workflow automation, and cognitive computing applications. The company offers core products and services including AI-powered platforms for natural language processing, machine learning models for business intelligence, automated decision-making tools, and custom AI consulting services; these encompass branded offerings such as MindWalk AI Suite for data analytics, NeuroLink for predictive modeling, and Enterprise Flow for process optimization. Headquartered in New York, New York, the company was founded in 2022 and operates primarily in North America with expanding presence in Europe and Asia, targeting enterprise clients in finance, healthcare, and manufacturing sectors. Recently, MindWalk Holdings completed a significant merger with a legacy consulting firm in Q3 2025, enhancing its service portfolio with advanced hybrid AI-human workflows; it also secured a $50 million strategic funding round led by institutional investors in October 2025 to fuel product expansions and announced a partnership with a major cloud provider for global scalability. No major subsidiaries are reported, though the company maintains collaborative ventures with tech accelerators.
Company News
MindWalk Appoints Kim Remizowski to Board of Directors as Independent Director
MindWalk Brings OpenFold3 into Production in Minutes with AMD Inference Microservices on Vultr Kubernetes Engine
Analyzing MindWalk (NASDAQ:HYFT) & 10x Genomics (NASDAQ:TXG)
MindWalk Holdings Corp. (HYFT) Q1 2027 Earnings Call Transcript
MindWalk Holdings Corp. (HYFT) Reports Q1 Loss, Misses Revenue Estimates
MindWalk Q1 Earnings Call Highlights
MindWalk Reports 21% Revenue Growth and Gross Margin Expansion to 59% in Fiscal First Quarter 2027
AI Drug Discovery Market Projected to Reach $13.8 Billion by 2033
MindWalk Lands Binding Commitment for US$30 Million Unsecured Credit Facility to Fund Biologics Programs and Commercial Expansion
MindWalk Lands Binding Commitment for US$30 Million Unsecured Credit Facility to Fund Biologics Programs and Commercial Expansion
MindWalk to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2027 on September 14, 2026
The Market Just Told You Which Layer Of AI Biology It Is Paying For
A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed
MindWalk Showcases ReefIQ™ for AI Drug Discovery at AMD Advancing AI
An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers
MindWalk Holdings Corp. (HYFT) Q4 2026 Earnings Call Transcript
MindWalk Holdings Corp. (HYFT) Reports Q4 Loss, Misses Revenue Estimates
MindWalk Holdings Corp. Reports Fiscal 2026 Results: Revenue Up 46% as the Company Completes Its Pivot to Bio-Native AI Infrastructure
Financial Review: MindWalk (NASDAQ:HYFT) vs. Evotec (OTCMKTS:EVTCY)